Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.49
FLDM's Cash to Debt is ranked higher than
55% of the 254 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.82 vs. FLDM: 0.49 )
FLDM' s 10-Year Cash to Debt Range
Min: 0.32   Max: No Debt
Current: 0.49

Equity to Asset 0.38
FLDM's Equity to Asset is ranked higher than
57% of the 234 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.63 vs. FLDM: 0.38 )
FLDM' s 10-Year Equity to Asset Range
Min: -7.63   Max: 0.89
Current: 0.38

-7.63
0.89
F-Score: 2
Z-Score: 1.16
M-Score: -2.50
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -44.92
FLDM's Operating margin (%) is ranked higher than
61% of the 251 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.33 vs. FLDM: -44.92 )
FLDM' s 10-Year Operating margin (%) Range
Min: -338.59   Max: -26.2
Current: -44.92

-338.59
-26.2
Net-margin (%) -44.81
FLDM's Net-margin (%) is ranked higher than
61% of the 251 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.44 vs. FLDM: -44.81 )
FLDM' s 10-Year Net-margin (%) Range
Min: -368.13   Max: -23.22
Current: -44.81

-368.13
-23.22
ROE (%) -34.35
FLDM's ROE (%) is ranked higher than
59% of the 227 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.21 vs. FLDM: -34.35 )
FLDM' s 10-Year ROE (%) Range
Min: -24.15   Max: -16.77
Current: -34.35

-24.15
-16.77
ROA (%) -15.68
FLDM's ROA (%) is ranked higher than
63% of the 256 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.22 vs. FLDM: -15.68 )
FLDM' s 10-Year ROA (%) Range
Min: -67.71   Max: -14.33
Current: -15.68

-67.71
-14.33
ROC (Joel Greenblatt) (%) -286.61
FLDM's ROC (Joel Greenblatt) (%) is ranked higher than
59% of the 255 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.14 vs. FLDM: -286.61 )
FLDM' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -839.76   Max: -156.13
Current: -286.61

-839.76
-156.13
Revenue Growth (%) -46.00
FLDM's Revenue Growth (%) is ranked higher than
53% of the 189 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.40 vs. FLDM: -46.00 )
FLDM' s 10-Year Revenue Growth (%) Range
Min: 0   Max: -36.3
Current: -46

EBITDA Growth (%) -57.30
FLDM's EBITDA Growth (%) is ranked higher than
53% of the 163 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.10 vs. FLDM: -57.30 )
FLDM' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: -55.5
Current: -57.3

EPS Growth (%) -58.30
FLDM's EPS Growth (%) is ranked higher than
51% of the 167 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.30 vs. FLDM: -58.30 )
FLDM' s 10-Year EPS Growth (%) Range
Min: 0   Max: -53.4
Current: -58.3

» FLDM's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

FLDM Guru Trades in Q4 2013

Paul Tudor Jones 11,992 sh (New)
RS Investment Management 280,092 sh (New)
Chuck Royce Sold Out
PRIMECAP Management 3,484,821 sh (-7.52%)
Jim Simons 80,900 sh (-40.47%)
» More
Q1 2014

FLDM Guru Trades in Q1 2014

RS Investment Management 309,100 sh (+10.36%)
PRIMECAP Management 3,484,821 sh (unchged)
Jim Simons Sold Out
Paul Tudor Jones Sold Out
» More
Q2 2014

FLDM Guru Trades in Q2 2014

Jim Simons 49,500 sh (New)
RS Investment Management 524,648 sh (+69.73%)
PRIMECAP Management 3,651,332 sh (+4.78%)
» More
Q3 2014

FLDM Guru Trades in Q3 2014

RS Investment Management 536,748 sh (+2.31%)
PRIMECAP Management 3,689,632 sh (+1.05%)
Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with FLDM

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
PRIMECAP Management 2013-06-30 Add 31.95%0.02%$16 - $19.04 $ 30.1472%3746323
PRIMECAP Management 2013-03-31 Add 113.65%0.04%$14.27 - $19.38 $ 30.1479%2839232
PRIMECAP Management 2012-12-31 Add 495.25%0.03%$13.63 - $17.02 $ 30.14104%1328900
PRIMECAP Management 2012-09-30 New Buy0.01%$12.8 - $17.15 $ 30.14104%223250
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 5.50
FLDM's P/B is ranked higher than
67% of the 277 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.46 vs. FLDM: 5.50 )
FLDM' s 10-Year P/B Range
Min: 3.4   Max: 12.53
Current: 5.5

3.4
12.53
P/S 7.89
FLDM's P/S is ranked higher than
62% of the 277 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.11 vs. FLDM: 7.89 )
FLDM' s 10-Year P/S Range
Min: 0.94   Max: 16.73
Current: 7.89

0.94
16.73
Current Ratio 4.86
FLDM's Current Ratio is ranked higher than
87% of the 250 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.56 vs. FLDM: 4.86 )
FLDM' s 10-Year Current Ratio Range
Min: 1.13   Max: 8.73
Current: 4.86

1.13
8.73
Quick Ratio 4.24
FLDM's Quick Ratio is ranked higher than
85% of the 250 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.16 vs. FLDM: 4.24 )
FLDM' s 10-Year Quick Ratio Range
Min: 0.86   Max: 8.11
Current: 4.24

0.86
8.11

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 1.16
FLDM's Price/Median PS Value is ranked higher than
77% of the 277 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.36 vs. FLDM: 1.16 )
FLDM' s 10-Year Price/Median PS Value Range
Min: 0.14   Max: 2.04
Current: 1.16

0.14
2.04
Earnings Yield (Greenblatt) -4.90
FLDM's Earnings Yield (Greenblatt) is ranked higher than
64% of the 248 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.80 vs. FLDM: -4.90 )
FLDM' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0   Max: 0
Current: -4.9

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare: » details
Traded in other countries:FLB.Germany
Fluidigm Corp is a Delaware Corporation formed in May, 1999. The Company develops, manufacture, and market microfluidic systems to academic institutions, clinical laboratories, and pharmaceutical, biotechnology, and agricultural biotechnology (Ag-Bio) companies in growth markets, such as single-cell genomics, applied genotyping, and sample preparation for targeted resequencing. These systems are designed to simplify experimental workflow, increase throughput, and reduce costs, while providing the excellent data quality demanded by customers. The current markets for its products include life science research, clinical research, and Ag-Bio. The proprietary microfluidic systems consist of instruments and consumables, including integrated fluidic circuits (IFCs), assays, and reagents. The Company's primary area of development within life science research is genetic analysis, the study of genes and their functions. Genetic analysis techniques, such as SNP genotyping, genotyping by sequencing, and genotyping by real-time PCR analysis, have become increasingly useful in Ag-Bio applications, including wildlife population studies, agricultural quality control, and commercial genetic engineering and identification. It actively market four microfluidic systems, including 18 different commercial IFCs for nucleic acid analysis, as well as three families of assay chemistries. Its systems are based on one or more IFCs designed for particular applications and include specialized reagents, instrumentation, and software. The Company distributes its microfluidic systems through its direct sales force and support organizations located in North America, Europe, and Asia-Pacific, and through distributors or sales agents in several European, Latin American, Middle Eastern, and Asia-Pacific countries. It has sold its C1 Single-Cell Auto Prep, BioMark, BioMark HD, EP1, and Access Array systems to the academic institutions, clinical laboratories, and pharmaceutical, biotechnology and Ag-Bio companies. The Company has sold approximately 920 systems to customers in over 35 countries. Its microfluidic systems and instrumentation for commercial sale, as well as for internal research and development purposes, are manufactured at its facilities in Singapore. The Company also manufactures IFCs for research and development and its assay chemistries at its headquarters in South San Francisco, California. It competes with companies such as Affymetrix, Inc., Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., Illumina, Inc., Life Technologies Corporation (now part of Thermo Fisher Scientific), LGC Limited, Luminex Corporation, NanoString Technologies, Inc., PerkinElmer, Inc. (through its acquisition of Caliper Life Sciences, Inc.), RainDance Technologies, Inc., Roche Applied Science (a division of Roche Diagnostics Corporation), Sequenom, Inc., Thermo Fisher Scientific Inc., and WaferGen Bio-Systems, Inc.
» More Articles for FLDM

Headlines

Articles On GuruFocus.com
No related article found.


More From Other Websites
Fluidigm's (FLDM) New Workflow to Allow High Throughput Nov 19 2014
Fluidigm (FLDM) Now a Strong Buy on Key Product Releases Nov 18 2014
Fluidigm Announces New High Throughput Workflow for Single-Cell mRNA Sequencing Nov 18 2014
FLUIDIGM CORP Financials Nov 14 2014
Genome testing is now easy, fast and pretty Nov 14 2014
Fluidigm Ushers in a New Era of Customer Experience Nov 10 2014
10-Q for Fluidigm Corp. Nov 08 2014
FLUIDIGM CORP Files SEC form 10-Q, Quarterly Report Nov 06 2014
Fluidigm posts 3Q loss Oct 30 2014
FLUIDIGM CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Oct 30 2014
October 30, 2014 Fluidigm Reports Q3 2014 Results - Strong Q3 2014 Organic Revenue Growth of 35%... Oct 30 2014
Fluidigm Reports Q3 2014 Results Oct 30 2014
Q3 2014 Fluidigm Corp Earnings Release - After Market Close Oct 30 2014
October 21, 2014 Fluidigm to Announce Q3 2014 Financial Results and Host Conference Call for... Oct 22 2014
October 21, 2014 Oct 22 2014
Will Fluidigm (FLDM) Continue to Surge Higher? Oct 22 2014
Fluidigm to Announce Q3 2014 Financial Results and Host Conference Call for Investors Oct 21 2014
Fluidigm Redefines Single-Cell Whole Exome Sequencing Oct 02 2014
Stanford Researchers Use Single-Cell Mass Cytometry to Predict Recovery Time from Surgery Sep 25 2014
FLUIDIGM CORP Files SEC form 8-K, Entry into a Material Definitive Agreement Sep 19 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK